HIV post-exposure prophylaxis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 59: | Line 59: | ||
*Pregnancy test | *Pregnancy test | ||
== | ==Management== | ||
===Negligible Risk=== | ===Negligible Risk=== | ||
*NOT recommended | *NOT recommended | ||
| Line 81: | Line 69: | ||
;CDC no longer recommends that the severity of exposure be used to determine the number of drugs to be offered in an HIV PEP regimen, and a regimen containing 3 (or more) antiretroviral drugs is now recommended routinely for all occupational exposures to HIV. <ref>Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. August 6, 2013. http://www.jstor.org/stable/10.1086/672271 DOI: 10.1086/672271 </ref> | ;CDC no longer recommends that the severity of exposure be used to determine the number of drugs to be offered in an HIV PEP regimen, and a regimen containing 3 (or more) antiretroviral drugs is now recommended routinely for all occupational exposures to HIV. <ref>Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. August 6, 2013. http://www.jstor.org/stable/10.1086/672271 DOI: 10.1086/672271 </ref> | ||
===National Clinician's Post-Exposure Prophylaxis Hotline=== | ===National Clinician's Post-Exposure Prophylaxis Hotline=== | ||
*1-888-448-4911, call for expert advice | *1-888-448-4911, call for expert advice | ||
==See Also== | ==See Also== | ||
| Line 98: | Line 78: | ||
==Source== | ==Source== | ||
<references/> | |||
[[Category:ID]] | [[Category:ID]] | ||
Revision as of 05:03, 15 January 2015
Background
- Also known as Post-Exposure Prophylaxis (PEP)
- ~79% transmission reduction
- Initiate ASAP (goal = 1-2 hours)
- >36 hours: normally deferred, unless particularly high risk
- Common side-effects = constitutional, gastrointestinal
Exposure Transmission Risk
| Exposure^ |
Risk |
| Percutaneous | 0.3% |
| Mucocutaneous | 0.09% |
| Needle-sharing injection drug | 0.7% |
| Receptive anal intercourse | 0.5% |
| Receptive penile-vaginal intercourse | 0.1% |
| Insertive anal intercourse | 0.07% |
| Insertive penile-vaginal intercourse | 0.05% |
| Receptive oral (male) intercourse | 0.01% |
| Insertive oral (male) intercourse | 0.005% |
^assumes no condom use
High Risk Exposures
Source
- Symptomatic HIV/AIDS
- Acute seroconversion
- High viral load
Exposure
- Deep injuries
- Visible blood on device
- Injuries sustained placing a catheter in a vein/artery
Workup (Before Giving)
- CBC
- C7
- LFTs
- Pregnancy test
Management
Negligible Risk
- NOT recommended
Substantial Risk
- CDC preferred regimen:
- Raltegravir (isentress) 400 mg PO twice daily, plus
- Truvada (tenofovir 300 mg + emtricitabine 200 mg) 1 PO once daily
- CDC no longer recommends that the severity of exposure be used to determine the number of drugs to be offered in an HIV PEP regimen, and a regimen containing 3 (or more) antiretroviral drugs is now recommended routinely for all occupational exposures to HIV. [1]
National Clinician's Post-Exposure Prophylaxis Hotline
- 1-888-448-4911, call for expert advice
See Also
Source
- ↑ Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. August 6, 2013. http://www.jstor.org/stable/10.1086/672271 DOI: 10.1086/672271